SULF-15
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SULF-15 (SULF-15).
SULF-15 is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels (K_ATP), leading to cell membrane depolarization, calcium influx, and exocytosis of insulin.
| Metabolism | Primarily metabolized by CYP2C9 to active and inactive metabolites; hepatic and renal elimination. |
| Excretion | Renal excretion accounts for 60-70% of elimination as unchanged drug; biliary/fecal excretion accounts for 20-30% as metabolites and parent compound. |
| Half-life | Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to >30 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 85-90% bound to albumin. |
| Volume of Distribution | 0.8-1.2 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 75-90%; Intramuscular: 100%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 1-5 minutes; Intramuscular: 10-15 minutes. |
| Duration of Action | Oral: 6-12 hours; Intravenous: 4-8 hours; Intramuscular: 6-10 hours. Duration increases with higher doses and in renal impairment. |
| Molecular Weight | 415.3 |
150 mg orally twice daily for 14 days.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | CrCl >50 mL/min: no adjustment; CrCl 30-50 mL/min: 75 mg twice daily; CrCl <30 mL/min: 75 mg once daily; hemodialysis: 75 mg after each dialysis session. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended. |
| Pediatric use | For children 2-12 years: 2.5 mg/kg orally twice daily (max 150 mg per dose) for 14 days; for infants <2 years: not established. |
| Geriatric use | No specific dose adjustment based on age alone; use with caution due to age-related renal decline; follow renal adjustment guidelines. |
| 1st trimester | Contraindicated in first trimester due to risk of teratogenicity. |
| 2nd trimester | Contraindicated in second trimester due to risk of fetal toxicity. |
| 3rd trimester | Contraindicated in third trimester due to risk of neonatal complications. |
Clinical note
Comprehensive clinical and safety monograph for SULF-15 (SULF-15).
| Placental transfer | Extensive placental transfer observed in animal studies; presumed to cross human placenta based on molecular weight and lipophilicity. |
| Breastfeeding | Contraindicated during breastfeeding as it is excreted in human milk and may cause adverse effects in nursing infants. |
| Lactation Rating |
■ FDA Black Box Warning
Increased risk of cardiovascular mortality compared to diet alone or diet plus insulin, as observed in the University Group Diabetes Program (UGDP) study.
| Serious Effects |
PregnancyBreastfeedingHypersensitivity to SULF-15 or any componentSevere hepatic impairmentSevere renal impairment
| Precautions | Hypoglycemia, especially in elderly or debilitated patients, renal or hepatic impairment, and in those using other hypoglycemic agents. May cause hemolytic anemia in G6PD deficiency. Weight gain. Increased cardiovascular risk. |
| Food/Dietary | Avoid folic acid-rich foods (e.g., leafy greens) as they may antagonize antibacterial effect. Limit vitamin C supplementation to prevent urine acidification and crystalluria. Alcohol may cause disulfiram-like reaction (nausea, vomiting, headache). |
Loading safety data…
| L5 - Contraindicated |
| Teratogenic Risk | SULF-15 is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies. First trimester: high risk of neural tube defects and cardiovascular malformations. Second and third trimesters: risk of fetal nephrotoxicity and oligohydramnios. Avoid in women of childbearing potential unless effective contraception is used. |
| Fetal Monitoring | Monitor maternal renal function (serum creatinine, BUN) and liver enzymes monthly. Perform fetal ultrasound every 4 weeks to assess amniotic fluid volume and fetal growth. Monitor for signs of fetal distress with non-stress test or biophysical profile after 28 weeks gestation. |
| Fertility Effects | SULF-15 has been associated with reduced fertility in animal studies, including impaired spermatogenesis in males and ovulation disruption in females. In humans, reversible oligospermia has been reported. Women may experience menstrual irregularities. Contraception is recommended during therapy. |
| Clinical Pearls | SULF-15 (sulfadiazine) is a short-acting sulfonamide. Always confirm sulfa allergy before administration. Use with caution in patients with G6PD deficiency due to risk of hemolytic anemia. Monitor renal function and ensure adequate hydration to prevent crystalluria. Avoid in pregnancy (near term) and lactation due to risk of kernicterus. Potentiates warfarin, phenytoin, and oral hypoglycemics by displacing from protein binding. |
| Patient Advice | Take with a full glass of water and maintain good fluid intake to prevent kidney crystals. · Complete the full course of therapy even if symptoms improve. · Avoid sun exposure and use sunscreen; this drug may cause photosensitivity. · Report any skin rash, fever, sore throat, or unusual bleeding promptly. · Do not take if you have a history of sulfonamide allergy. |